Evidence map›Paper›PMID 18380891›Full record

ArticleBMC cell biology2008

Epidermal growth factor receptor levels are reduced in mice with targeted disruption of the protein kinase A catalytic subunit.

Morten P Oksvold, Ane Funderud, Anne-Katrine Kvissel, Ellen Skarpen, Heidi Henanger, Henrik S Huitfeldt, Bjørn S Skålhegg, Sigurd Ørstavik

Open access · goldAbstract read
In one paragraph

Article in BMC cell biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Morten P OksvoldInstitute of Pathology, Rikshospitalet University Hospital, University of Oslo, Norway. moroks@rr-research.no
Ane Funderud
Anne-Katrine Kvissel
Ellen Skarpen
Heidi Henanger
Henrik S Huitfeldt
Bjørn S Skålhegg
Sigurd Ørstavik
University of Oslo · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermal Growth Factor Receptor (EGFR) is a key target molecule in current treatment of several neoplastic diseases. Hence, in order to develop and improve current drugs targeting EGFR signalling, an accurate understanding of how this signalling pathway is regulated is required. It has recently been demonstrated that inhibition of cAMP-dependent protein kinase (PKA) induces a ligand-independent internalization of EGFR. Cyclic-AMP-dependent protein kinase consists of a regulatory dimer bound to two catalytic subunits.

resultsWe have investigated the effect on EGFR levels after ablating the two catalytic subunits, Calpha and Cbeta in two different models. The first model used targeted disruption of either Calpha or Cbeta in mice whereas the second model used Calpha and Cbeta RNA interference in HeLa cells. In both models we observed a significant reduction of EGFR expression at the protein but not mRNA level.

conclusionOur results suggest that PKA may represent a target that when manipulated can maintain EGFR protein levels at the single cell level as well as in intact animals.

Indexed as

AnimalsCyclic AMP-Dependent Protein Kinase Catalytic SubunitsDown-RegulationEpidermal Growth FactorErbB ReceptorsGene Expression Regulation, EnzymologicHeLa CellsHumansMiceMice, KnockoutRNA InterferenceRNA, MessengerSignal TransductionCyclic AMP-Dependent Protein Kinase Catalytic SubunitsEpidermal Growth FactorErbB ReceptorsRNA, Messenger

Identifiers

PMID18380891
PMCPMC2324083
OpenAlexW2074515936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.